AI in CDM DMEG
AI (Artificial Intelligence) is already revolutionising the clinical data management industry, and its impact is only just beginning. This cutting-edge technology holds the power to automate key tasks such as data collection, analysis, and interpretation, driving efficiency, improving accuracy, and enabling data managers to make faster, more informed decisions in clinical trials. Yet, despite its immense potential, embracing AI in CDM comes with its own set of challenges, ranging from data privacy concerns to bias mitigation, implementation hurdles, and regulatory compliance.
The AI in CDM DMEG is here to bring together collaborators from pharma, biotech, CROs, and technology providers. Building on the inspiring conversations already sparked at ACDM symposia and annual conferences, we aim to lead the way in shaping how AI can be safely and effectively integrated into CDM. Together, we’ll explore the future of AI, sharing insights, best practices, and strategies for a successful adoption across the industry.
We’re calling for passionate volunteers to help shape this exciting new DMEG. This is your chance to play a pivotal role in guiding the safe, effective adoption of AI in clinical data management and making a lasting impact on the future of the industry.
AI in CDM DMEG
AI (Artificial Intelligence) is already revolutionising the clinical data management industry, and its impact is only just beginning. This cutting-edge technology holds the power to automate key tasks such as data collection, analysis, and interpretation, driving efficiency, improving accuracy, and enabling data managers to make faster, more informed decisions in clinical trials. Yet, despite its immense potential, embracing AI in CDM comes with its own set of challenges, ranging from data privacy concerns to bias mitigation, implementation hurdles, and regulatory compliance.
The AI in CDM DMEG is here to bring together collaborators from pharma, biotech, CROs, and technology providers. Building on the inspiring conversations already sparked at ACDM symposia and annual conferences, we aim to lead the way in shaping how AI can be safely and effectively integrated into CDM. Together, we’ll explore the future of AI, sharing insights, best practices, and strategies for a successful adoption across the industry.
We’re calling for passionate volunteers to help shape this exciting new DMEG. This is your chance to play a pivotal role in guiding the safe, effective adoption of AI in clinical data management and making a lasting impact on the future of the industry.
Members
Ashley Howard | DMEG Chair
Director, Senior Asset Lead | Pfizer
As an experienced data manager leader, Ashley has worked across therapeutic area disciplines within both the pharmaceutical and CRO industries. He has over 14 years experience in Clinical Data Management. Ashley joined the Oncology team within the Data Monitoring and Management department at Pfizer in 2018 and is currently a Director, Senior Asset Lead supporting the development of a number of key, pivotal compounds.
Ashley Howard | DMEG Chair
Director, Senior Asset Lead | Pfizer
As an experienced data manager leader, Ashley has worked across therapeutic area disciplines within both the pharmaceutical and CRO industries. He has over 14 years experience in Clinical Data Management. Ashley joined the Oncology team within the Data Monitoring and Management department at Pfizer in 2018 and is currently a Director, Senior Asset Lead supporting the development of a number of key, pivotal compounds.
Intersted in Joining?
The AI in CDM DMEG welcome new members to the group to help shape the way in which we adopt this technology safely and effectively. To join, please click here.